Previous close | 8.26 |
Open | 8.30 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's range | 7.90 - 8.30 |
52-week range | 6.97 - 21.50 |
Volume | |
Avg. volume | 265,126 |
Market cap | 367.711M |
Beta (5Y monthly) | 2.50 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.45 |
Earnings date | 11 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 42.30 |
PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent).In June 2022, the PTAB denied institution of the PGRs finding the challenger failed to establish that any of the claims of ‘257 Patent and ‘259 Patent are unpatentable. LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient a
She will remain a member of the COMPASS Pathways Board of DirectorsLONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. She will remain a member of the COMPASS Pathways Board of Directors, while her executive res
LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Jefferies Healthcare Conference at 3:30 pm ET on June 8, 2023. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be accessible for 30 days f
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on June 5, is believed to be the longest clinical study of psilocybin ever conducted LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated
Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS)Q1 2023 Earnings CallMay 11, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and thank you for standing by.
LONDON, May 11, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program underway, patients have been treated in both trialsCPT® III code for in-person psychedelic therapy support accepted by the American Medical AssociationCash position at 31 March 2023 of $117.1 million, additional $26.9 million net cash raised through ATM facility to date in the second quarterConference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care compan
After a sharp rally in 2021, most stocks in the biotech industry's psychedelic segment are a shadow of their former selves. It'll be some time before the details surrounding the codes are finalized and won't be published in full until July of this year.
LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2023, and provide an update on recent business developments on 11 May 2023. The management team will host a conference call at 8:00am ET (1:00pm UK) on 11 May 2023. To access the call, please register in advance here to obtain a
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approvedLONDON and SAN JOSE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and MAPS Public Benefit Corporation (MAPS PBC), a clinical-stage company dedicated to changing the way mental health conditions are treat
With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (NASDAQ: ATAI) is having a rough go of things lately. When faced with such a discrepancy between recent performance and projected future returns, investors are right to hesitate to invest in this super-risky biotech stock. Let's take a peek at what's going wrong with Atai so that we can figure out if it's capable of surviving in the near term, and if it is, whether that makes it a buy.
LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 22nd Annual Needham Virtual Healthcare Conference at 9:30 am ET on April 19, 2023. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be ac
Enterprising investors who pay attention to this can set themselves up for future success by buying into great growth stocks while in the hard landing phase of the volatility. Two biopharma stocks are particularly appealing right now as buy candidates before the next bull market has a chance to buoy their shares once again. It develops liquid biopsies for cancer screening, treatment selection, treatment efficacy evaluation, and recurrence detection, which means that patients don't need to experience the invasiveness of a traditional biopsy to get the health information their doctors need to determine a course of treatment.
Specifically, there are no guarantees that positive early results will lead to positive later-stage clinical trials results, despite yearslong efforts put in to develop these drugs and therapies. More often than not, pharma and biotech investors can only gauge the chances of a company's success by weighing the results of its clinical trials against its available cash runway.
LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows: Cowen 43rd Annual Health Care Conference: ‘Neuropsych Panel’ at 12:50pm ET on March 6, 2023 and host investor meetingsOppenheimer 33rd Annual Healthcare Conference: presentation at 10:00am ET on March 13, 2023 and hos
Again, my name is Steve Schultz. Dr. Guy Goodwin, our chief medical officer, is unable to join us today, so Kabir will be covering clinical development. Before we begin, let me remind everyone that during the call today, the team will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended.
Highlights: Phase 3 pivotal program underway - important updates announcedPhase 3 long term follow up definedCash position at 31 December 2022 of $143.2 millionConference call today at 8:00am ET (1:00pm UK) LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gav
Conference call to be held at 8:00am ET (1:00pm UK)LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2022, and provide an update on recent business developments on 28 February 2023. The management team will host a conference call at 8:00am ET (1:00pm UK) on 28 Fe
Analysts are bearish, for example, on the three stocks that have helped the most in Wood's Ark Innovation ETF (NYSEMKT: ARKK) trouncing the market so far in 2023. Here are three Cathie Wood stocks that could more than double in 12 months, according to Wall Street. Wood owns shares of Intellia Therapeutics (NASDAQ: NTLA) in two of her ETFs -- the flagship Ark Innovation ETF and the Ark Genomic Revolution ETF (NYSEMKT: ARKG).
Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.
12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder New data from COMPASS’ phase 2b trial, also presented at ACNP, validate potential of COMP360 psilocybin therapy in treatment-resistant depression LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to acc
Just as the idea of using psychedelic medicines to treat mental illnesses is gaining traction in society, psychedelics-focused biotech companies are becoming legitimate and lucrative investments that could help your portfolio in the future. Before you can appreciate which psychedelics players are worth investing in, you'll need to get a feeling for where the industry is going and how it's changing. As inflation surges in the U.S., the Federal Reserve is trying to stop it by hiking the federal funds rate, which ultimately determines how much interest companies need to pay when they take out fresh debt.
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be acc
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS)Q3 2022 Earnings CallNov 03, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, ladies and gentlemen.